Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) was up 6.4% during trading on Tuesday . The stock traded as high as $5.19 and last traded at $5.15, with a volume of 539,096 shares changing hands. The stock had previously closed at $4.84.

Several equities research analysts have commented on ARLZ shares. Chardan Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aralez Pharmaceuticals in a research note on Sunday. Guggenheim reiterated a “buy” rating and issued a $12.00 price target on shares of Aralez Pharmaceuticals in a report on Monday.

The company’s market capitalization is $329.52 million. The firm’s 50-day moving average is $3.72 and its 200-day moving average is $4.26.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. The firm had revenue of $12.60 million for the quarter, compared to the consensus estimate of $9.70 million. The business’s quarterly revenue was up 142.3% compared to the same quarter last year. On average, equities analysts expect that Aralez Pharmaceuticals Inc. will post ($0.99) EPS for the current fiscal year.

In other Aralez Pharmaceuticals news, insider James Patrick Tursi bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 20th. The shares were acquired at an average cost of $3.75 per share, for a total transaction of $37,500.00. Following the transaction, the insider now directly owns 179,368 shares in the company, valued at $672,630. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.